Truist initiated coverage of Vanda Pharmaceuticals with a Buy rating and $18 price target. With three commercial drugs commanding $200M in sales plus "a slew of higher value near-commercial-ready assets nearing launch," the firm sees Vanda's reformulation of lead asset Fanapt launching with improved economics into a competitive schizophrenia and bipolar market differentiated by lower weight gain risk. "More interestingly" is Vanda's first-mover advantage of Nereus into adjunct therapy for GLP-1 induced vomiting, as the firm sees this as a derisked $1B opportunity.
